• BrothertonJulia M LJMLNational HPV Vaccination Program Register, VCS, East Melbourne, Victoria, Australia; School of Population and Global Health, University of Melbourne, Parkville, Victoria, Australia. Electronic address: jbrother@vcs.org.au. and Paul N Bloem.
• National HPV Vaccination Program Register, VCS, East Melbourne, Victoria, Australia; School of Population and Global Health, University of Melbourne, Parkville, Victoria, Australia. Electronic address: jbrother@vcs.org.au.
• Best Pract Res Clin Obstet Gynaecol. 2018 Feb 1; 47: 42-58.

AbstractPersistent oncogenic human papillomavirus (HPV) is the cause of cervical cancer, as well as cancers of the anus, penis, vulva, vagina and oropharynx. There is good evidence that prophylactic HPV vaccines are immunogenic and effective against targeted-type HPV infections and type-specific genital lesions, including high-grade cervical intraepithelial neoplasia (CIN), when administered prior to HPV infection. There is good evidence that HPV vaccines are safe in population usage, with the most frequent adverse event being injection-site reactions. There is evidence to support some cross-protection against non-targeted types occurring following the administration of HPV vaccines. There is limited evidence suggesting that HPV vaccines may be beneficial in preventing future disease in women treated for high-grade CIN. This chapter focuses on the accumulated evidence regarding the global use of the three licensed HPV vaccines including safety, immunogenicity, duration of protection, effectiveness, coverage to date and barriers to higher coverage.Copyright © 2018 Elsevier Ltd. All rights reserved.

30 keywords...

hide…